LDLR promotes growth and invasion in renal cell carcinoma and activates the EGFR pathway.

Gui-Ming Zhang, Wei Chen, Yu Yao, Lei Luo, Li-Jiang Sun

Neoplasma 2022 Jan

filter terms:

Previous studies identified an association of low-density lipoprotein (LDL) levels and LDL receptor (LDLR) with renal cell carcinoma (RCC) development. This study investigated the expression and roles of LDLR in RCC. LDLR expression was examined in clear cell RCC (ccRCC) and adjacent normal kidney tissues, and its clinicopathological significance was analyzed. The role of LDLR in RCC cell proliferation, cell cycle, and invasion were assessed in RCC cells with LDLR stable knockdown. LDLR expression was higher in ccRCC tissues than in normal kidney tissues and increased with RCC progression. LDLR knockdown in RCC cells inhibited cell growth, migration and invasion, and induced G1/S cell cycle arrest. We identified an interaction between LDLR and EGFR, and EGFR signaling protein expression was reduced after LDLR knockdown. Our findings reveal that LDLR plays an important role in RCC carcinogenesis, suggesting that LDL and LDLR might be potential targets for therapeutic intervention in RCC.

Citation

Gui-Ming Zhang, Wei Chen, Yu Yao, Lei Luo, Li-Jiang Sun. LDLR promotes growth and invasion in renal cell carcinoma and activates the EGFR pathway. Neoplasma. 2022 Jan;69(1):113-122